Determining the therapies' capacity to neutralize the SARS-CoV-2 virus is one of the most crucial evaluation metrics in the development of COVID-19 medications and vaccines. In order to achieve this, we created the SARS-CoV-2 pseudovirus and offered services for neutralization tests based on similar pseudoviruses. While pseudoviruses lack the virus's nucleic acid and are unable to replicate within the body, they still contain the proteins required for live viruses to infect cells. As a result, they are extremely safe and adaptable, which makes them perfect instruments for researching how well medications and vaccines kill viruses.

Pseudovirus Neutralization Assay for SARS-CoV-2

The spike protein (S), membrane protein (M), envelope protein (E), and nucleocapsid protein (N) are the four structural proteins of SARS-CoV-2. S protein is one of them; it is linked to the attachment of viruses and their entry into target cells, and it is thought to be essential for initiating the infection process. Furthermore, S protein is crucial for triggering protective humoral and cellular immune responses during SASR-CoV-2 infection. Consequently, S protein has emerged as the most desirable target for the creation of medications and vaccines against SARS-CoV-2.